RxDoctor Payments Data

Isaac Ball

Surgical · Farmington, MENPI 1205067519

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $189 and has fallen 72.8% since, to $51 in 2025.

$615in general payments, 2019–2025

Across 27 payments — averaging $22.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$123
  • Johnson & Johnson$105
  • AbbVie$98
  • Teleflex LLC$79
  • Sumitomo Pharma America, Inc.$43
  • Pfizer$37
  • plus $130 from 6 others

What the payments were for

  • Food & beverage$615100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$615 in reported general payments places this provider in the 80th percentile of 105 surgical providers in Maine.

See all surgical providers in Maine

Medicare billing

Part B allowed, 2024
$75,308
Medicare patients
343
Services billed
1,771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide12$165,956
MyrbetriqMirabegron93$66,285
PremarinEstrogens, Conjugated86$37,524
Solifenacin Succinate405$21,517
GemtesaVibegron15$14,660
Tamsulosin Hcl730$8,700
Oxybutynin Chloride ErOxybutynin Chloride146$5,308
Potassium Citrate ErPotassium Citrate57$4,962
Testosterone28$4,287
Trimethoprim40$3,890
Methenamine Hippurate25$2,958
Cefpodoxime Proxetil11$2,955
Cefdinir156$2,942
Estradiol29$2,550
NitrofurantoinNitrofurantoin Macrocrystal41$1,974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$105$165,95612 claims
Astellas Pharma US IncMyrbetriq$123$66,28593 claims
PfizerPremarin$37$37,52486 claims
Sumitomo Pharma America, Inc.Gemtesa$43$14,66015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 105 surgical providers in Maine.

Other surgical in Farmington

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →